FDA Approves Xolair (omalizumab) Prefilled Syringe for Self-Injection Across All Indications
●  Xolair for self-injection offers healthcare providers and appropriate patients another administration option for more flexibility in managing their treatmentBasel, 13 April 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the company ’s supplemental Biologics License Application for Xolair® (omalizumab) prefilled syringe for self-injection across all approved U.S. indications.1 Xolair is the only FDA-approved biologic designed to target and block immunoglobulin E (IgE) for the treatment of moderate to severe persistent allergic ...
Source: Roche Investor Update - April 13, 2021 Category: Pharmaceuticals Source Type: news

FDA Approves Xolair (omalizumab) Prefilled Syringe for Self-Injection Across All Indications
●  Xolair for self-injection offers healthcare providers and appropriate patients another administration option for more flexibility in managing their treatmentBasel, 13 April 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the company ’s supplemental Biologics License Application for Xolair® (omalizumab) prefilled syringe for self-injection across all approved U.S. indications.1 Xolair is the only FDA-approved biologic designed to target and block immunoglobulin E (IgE) for the treatment of moderate to severe persistent allergic ...
Source: Roche Media News - April 13, 2021 Category: Pharmaceuticals Source Type: news

Arthritis Drug May Curb Myocardial Damage in Acute STEMI Arthritis Drug May Curb Myocardial Damage in Acute STEMI
Tocilizumab appears to improve myocardial salvage by helping tamp down the inflammatory overshoot that occurs during infarction and reperfusion.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 13, 2021 Category: Cardiology Tags: Cardiology News Source Type: news

Providing patient information leaflets following COVID-19 treatment, SPS
Following treatment for COVID-19 with tocilizumab, sarilumab or steroids, clinicians should provide suitable patient information leaflets at discharge. Forms attached to this page can be used by clinicians with patients to support the discharge process. The materials have been developed in conjunction with Dhivya Subramaniam, NHS England and NHS Improvement. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - April 7, 2021 Category: Consumer Health News Source Type: news

Repurposing tocilizumab in scleroderma patients may prevent early lung disease
(Michigan Medicine - University of Michigan) A phase 3 clinical trial finds an anti-inflammatory drug used in rheumatoid arthritis can preserve lung function in patients with systemic sclerosis. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - March 31, 2021 Category: International Medicine & Public Health Source Type: news

Interleukin6 blocking agents for treating COVID19: a living systematic review, Cochrane Library
Authors'conclusions On average, tocilizumab reduces all ‐cause mortality at D28 compared to standard care alone or placebo and probably results in slightly fewer serious adverse events than standard care alone or placebo. Nevertheless, tocilizumab probably results in little or no increase in the outcome clinical improvement (defined as hospital dischar ge or improvement measured by trialist‐defined scales) at D28. The impact of tocilizumab on other outcomes is uncertain or very uncertain. With the data available, we were not able to explore heterogeneity. Individual patient data meta‐analyses are needed to be able to...
Source: Current Awareness Service for Health (CASH) - March 25, 2021 Category: Consumer Health News Source Type: news

Can medicines that block interleukin-6 (a protein involved in immune responses) treat COVID-19?
This recently published Cochrane review examines the effects of a class of treatments on people with COVID-19.  Treating COVID-19 with tocilizumab (a medicine that blocks interleukin-6) reduces the numbers of people who die within 28 days of treatment, and probably results in fewer serious unwanted effects than placebo treatment.Studies of other medicines that block interleukin-6 to treat COVID-19 are under way. The authors of this review will update this review when results from them become available.COVID-19COVID-19 is an infectious respiratory disease caused by a type of virus called a coronavirus. If the infection...
Source: Cochrane News and Events - March 18, 2021 Category: Information Technology Authors: Katie Abbotts Source Type: news

Roche Says Actemra-Remdesivir Trial Fails to Cut Hospital Stays Roche Says Actemra-Remdesivir Trial Fails to Cut Hospital Stays
Swiss drugmaker Roche said on Thursday adding its drug Actemra to Gilead Sciences'Veklury medication, also called remdesivir, did not reduce hospital stays for patients with severe COVID-19 pneumonia.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - March 12, 2021 Category: Intensive Care Tags: Infectious Diseases News Source Type: news

Combo of Genentech, Gilead drugs fails Covid trial
The study is one of three late-stage clinical trials that Genentech has undertaken to assess the use of the rheumatoid arthritis drug Actemra in Covid patients with pneumonia. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 11, 2021 Category: Biotechnology Authors: Ron Leuty Source Type: news

Combo of Genentech, Gilead drugs fails Covid trial
The study is one of three late-stage clinical trials that Genentech has undertaken to assess the use of the rheumatoid arthritis drug Actemra in Covid patients with pneumonia. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - March 11, 2021 Category: American Health Authors: Ron Leuty Source Type: news

Tocilizumab Use Not Supported for Moderate-to-Severe COVID-19
THURSDAY, March 11, 2021 -- Tocilizumab is not associated with progression of COVID-19 among adults admitted to hospital with moderate-to-severe COVID-19, according to a study published online March 4 in The Lancet Respiratory Medicine. Arvinder S.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 11, 2021 Category: Pharmaceuticals Source Type: news

Roche provides update on the phase III REMDACTA trial of Actemra/RoActemra plus Veklury in patients with severe COVID-19 pneumonia
Basel, 11 March 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the global phase III randomised, double-blind, multicentre REMDACTA study of Actemra ®/RoActemra® (tocilizumab) plus Veklury® (remdesivir), versus placebo plus Veklury, did not meet its primary endpoint. This was measured by improved time to hospital discharge up to day 28 in patients with severe COVID-19 pneumonia receiving standard of care. No new safety signals were identified for Actemra/RoActemra in the REMDACTA trial. The study was conducted in collaboration with Gilead Sciences, Inc. (Source: Roche Media News)
Source: Roche Media News - March 11, 2021 Category: Pharmaceuticals Source Type: news

Roche provides update on the phase III REMDACTA trial of Actemra/RoActemra plus Veklury in patients with severe COVID-19 pneumonia
Basel, 11 March 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the global phase III randomised, double-blind, multicentre REMDACTA study of Actemra ®/RoActemra® (tocilizumab) plus Veklury® (remdesivir), versus placebo plus Veklury, did not meet its primary endpoint. This was measured by improved time to hospital discharge up to day 28 in patients with severe COVID-19 pneumonia receiving standard of care. No new safety signals were identified for Actemra/RoActemra in the REMDACTA trial. The study was conducted in collaboration with Gilead Sciences, Inc. (Source: Roche Investor Update)
Source: Roche Investor Update - March 11, 2021 Category: Pharmaceuticals Source Type: news

Tocilizumab Scores FDA Approval for SSc-ILD Tocilizumab Scores FDA Approval for SSc-ILD
Tocilizumab is the first biologic to be approved by the agency for adults with systemic sclerosis –associated interstitial lung disease, a rare, potentially life-threatening condition.FDA Approvals (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - March 8, 2021 Category: Drugs & Pharmacology Tags: Rheumatology News Alert Source Type: news

Tocilizumab cuts mortality risk in severely ill COVID-19 patients finds new trial conducted in India
Tocilizumab, an anti-inflammatory drug used to treat rheumatoid arthritis, improves outcomes in severely ill COVID-19 patients, finds the results of a new trial conducted in hospitals across India — one of the world ’ s most ethnically diverse countries. (Source: University of Bristol news)
Source: University of Bristol news - March 8, 2021 Category: Universities & Medical Training Tags: Health, International, Publications, Research; Faculty of Health Sciences, Bristol Medical School; Press Release Source Type: news

Tocilizumab cuts mortality risk in severely ill COVID-19 patients finds new trial conducted in India
(University of Bristol) Tocilizumab, an anti-inflammatory drug used to treat rheumatoid arthritis, improves outcomes in severely ill COVID-19 patients, finds the results of a new trial conducted in hospitals across India -- one of the world's most ethnically diverse countries. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 8, 2021 Category: International Medicine & Public Health Source Type: news

Roche ’s Actemra/RoActemra becomes the first biologic therapy approved by the FDA for slowing the rate of decline in pulmonary function in adults with systemic sclerosis-associated interstitial lung disease, a rare, debilitating condition
Basel, 05 March 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) approved Actemra®/RoActemra® (tocilizumab) subcutaneous injection for slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), a debilitating condition with limited treatment options. Actemra/RoActemra is the first biologic therapy approved by the FDA for the treatment of the disease. Systemic sclerosis (SSc), also known as scleroderma, is an often devastating autoimmune disease that worsens over time and has no ...
Source: Roche Investor Update - March 5, 2021 Category: Pharmaceuticals Source Type: news

Roche ’s Actemra/RoActemra becomes the first biologic therapy approved by the FDA for slowing the rate of decline in pulmonary function in adults with systemic sclerosis-associated interstitial lung disease, a rare, debilitating condition
Basel, 05 March 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) approved Actemra®/RoActemra® (tocilizumab) subcutaneous injection for slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), a debilitating condition with limited treatment options. Actemra/RoActemra is the first biologic therapy approved by the FDA for the treatment of the disease. Systemic sclerosis (SSc), also known as scleroderma, is an often devastating autoimmune disease that worsens over time and has no ...
Source: Roche Media News - March 5, 2021 Category: Pharmaceuticals Source Type: news

Does an Arthritis Drug Help Patients Battling Severe COVID? It Depends on the Study
WEDNESDAY, March 3, 2021 -- Two new studies suggest that the jury is still out on whether the arthritis drug tocilizumab helps those with severe COVID-19. Both reports were published recently in the New England Journal of Medicine. The first, from... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 3, 2021 Category: General Medicine Source Type: news

​IL - 6 Receptor Antagonists Benefit Critically Ill With COVID - 19 ​
Improved outcomes, including more organ support - free days, reduced mortality, seen with tocilizumab, sarilumab (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - March 2, 2021 Category: Respiratory Medicine Tags: Infections, Pharmacy, Pulmonology, Critical Care, Journal, Source Type: news

​IL-6 Receptor Antagonists Benefit Critically Ill With COVID-19​
TUESDAY, March 2, 2021 -- Treatment with interleukin-6 receptor antagonists tocilizumab and sarilumab improves outcomes among critically ill patients with COVID-19 receiving organ support in the intensive care unit (ICU), according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 2, 2021 Category: Pharmaceuticals Source Type: news

Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia, New England Journal of Medicine
This placebo-controlled Phase III study of tocilizumab in patients hospitalised with severe Covid-19 pneumonia found no improvement in clinical status (primary endpoint; between-group difference -1.0; 95% CI -2.5 to 0; p=0.31) or mortality (19.7% v 19.4%; p=0.94) at day 28. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - March 1, 2021 Category: Consumer Health News Source Type: news

COVID-19 rapid evidence summary: Tocilizumab for COVID-19, NICE (updated 24th February 2021)
Evidence summary updated at the request of NHS England because new evidence was identified: prepublication study results from the nationally prioritised platform study (Horby et al. 2021; the RECOVERY study), and a published randomised controlled trial (Veiga et al. 2021). (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - March 1, 2021 Category: Consumer Health News Source Type: news

Repurposed arthritis drug did not significantly improve severe COVID-19 pneumonia
(University of California - San Diego) A repurposed drug used to treat arthritis did not significantly improve the outcomes of patients with severe COVID-19 pneumonia. Tocilizumab did not significantly improve clinical status or mortality rate at 28 days for participants who received it compared to a placebo. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - March 1, 2021 Category: Infectious Diseases Source Type: news

Tocilizumab May Improve Lung Function in Early Systemic Sclerosis Tocilizumab May Improve Lung Function in Early Systemic Sclerosis
Treatment with tocilizumab could stabilize or improve lung function in people with early interstitial lung disease associated with systemic sclerosis.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - February 19, 2021 Category: Dermatology Tags: Rheumatology News Source Type: news

UK Interim Clinical Commissioning Policy for tocilizumab has been updated to cover a wider group of hospitalised COVID-19 positive patients, DHSC
NHS trusts/health boards are recommended to consider prescribing single dose of tocilizumab to eligible hospitalised patients with COVID-19 pneumonia, typically as adjuvant treatment to dexamethasone as standard of care, following announcement of findings of RECOVERY trial. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - February 19, 2021 Category: Consumer Health News Source Type: news

Coronavirus update: Tocilizumab is a life-saving treatment for severely ill patients
CORONAVIRUS is being attacked from all angles, with game-changing treatments driving down the fatality rate in hospitals. In a press briefing on Monday, the government's Chief Medical Officer suggests arthritis drug tocilizumab strengthens the fight against COVID-19. (Source: Daily Express - Health)
Source: Daily Express - Health - February 15, 2021 Category: Consumer Health News Source Type: news

COVID-19 rapid guideline: critical care in adults [NG159], NICE (updated 12th February 2021)
Updated On 12 February 2021, we added advice to follow NHS England's interim clinical commissioning policies on tocilizumab and sarilumab for treating critically ill patients with COVID-19 pneumonia. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - February 12, 2021 Category: Consumer Health News Source Type: news

New coronavirus drug: What is life-saving drug Tocilizumab?
A DRUG normally used for arthritis has provided hope for coronavirus patients in hospital. What is life-saving drug Tocilizumab? (Source: Daily Express - Health)
Source: Daily Express - Health - February 11, 2021 Category: Consumer Health News Source Type: news

Roche arthritis drug cuts deaths in hospitalized COVID-19 patients, study suggests
Roche's arthritis drug tocilizumab cuts the risk of death among patients hospitalized with severe COVID-19, also shortening the time to recovery and reducing the need for mechanical ventilation, a large clinical trial suggests. (Source: CBC | Health)
Source: CBC | Health - February 11, 2021 Category: Consumer Health News Tags: News/Health Source Type: news

Roche's Tocilizumab Cuts Deaths in Hospitalized COVID-19 Patients: Study Roche's Tocilizumab Cuts Deaths in Hospitalized COVID-19 Patients: Study
Roche's arthritis drug tocilizumab cuts the risk of death among patients hospitalized with severe COVID-19, also shortening the time to recovery and reducing the need for mechanical ventilation, results of a large trial showed on Thursday.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 11, 2021 Category: Consumer Health News Tags: Infectious Diseases News Source Type: news

Injected arthritis drug reduces risk of death from Covid-19 by 4%, study finds
The drug tocilizumab is used by rheumatoid arthritis patients in the UK because it can control swelling inside the body. It costs around £615 per four-week dose when used for that purpose. (Source: the Mail online | Health)
Source: the Mail online | Health - February 11, 2021 Category: Consumer Health News Source Type: news

Arthritis drug that helps Covid ICU patients has wider benefits, trial finds
Researchers say tocilizumab could also help patients on general wards and relieve pressure on NHSCoronavirus – latest updatesSee all our coronavirus coverageA rheumatoid arthritis drug previously found to save lives among intensive care patients with Covid could also help those receiving oxygen on general wards and reduce pressure on the NHS, researchers have found.A trial calledRemap-Cap revealed last month that the anti-inflammatory drugtocilizumab cut both the risk of death among Covid patients in intensive care and the length of time patients spent in such units.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - February 11, 2021 Category: Science Authors: Nicola Davis Tags: Coronavirus Medical research UK news World news Source Type: news

Arthritis drug saves lives and speeds recovery from Covid-19, trial shows
Tocilizumab cuts mortality risk by 15%, reduces need for ventilation and shortens time in hospital (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - February 11, 2021 Category: Pharmaceuticals Source Type: news

Arthritis drug tocilizumab cuts deaths from Covid
Giving it along with a steroid drug can help the sickest patients with Covid-19, research reveals. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - February 11, 2021 Category: Consumer Health News Source Type: news

Treatment of critically ill adults with Covid-19 pneumonia
Interim clinical commissioning policies are now available for tocilizumab and sarilumab for the treatment of critically ill adults with COVID-19 pneumonia. (Source: NHS Networks)
Source: NHS Networks - February 4, 2021 Category: UK Health Source Type: news

Interleukin-6 inhibitors (tocilizumab and sarilumab) for critically ill patients with COVID-19 pneumonia (adults), MHRA (published 1st February 2021)
NHS trusts / health boards are recommended to consider prescribing either tocilizumab or sarilumab to hospitalised patients being treated with non-invasive ventilation (high-flow nasal oxygen therapy or continuous positive airway pressure ventilation) or invasive mechanical. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - February 2, 2021 Category: Consumer Health News Source Type: news

Drug vignettes: Tocilizumab, CEBM (updated 20th January 2021)
Patients with severe COVID-19 can develop cytokine release syndrome ( “cytokine storm”) and are reported to have high circulating IL-6 concentrations. Tocilizumab is a recombinant humanized anti-human IgG1 monoclonal antibody directed against the interleukin-6 receptor (IL-6R). It has therefore been proposed to be of value in the management of severe COVID-19. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - January 22, 2021 Category: Consumer Health News Source Type: news

Tocilizumab Does Not Improve Outcomes in Severe COVID - 19
Tocilizumab plus standard care no better for improving clinical outcomes at 15 days and may increase mortality (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - January 21, 2021 Category: Respiratory Medicine Tags: Infections, Nursing, Pharmacy, Pulmonology, Critical Care, Journal, Source Type: news

Tocilizumab Does Not Improve Outcomes in Severe COVID-19
THURSDAY, Jan. 21, 2021 -- Tocilizumab plus standard care is not superior to standard care alone for improving clinical outcomes among patients with severe or critical COVID-19 and may increase mortality, according to a study published online Jan.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 21, 2021 Category: Pharmaceuticals Source Type: news

Arthritis drug hailed by Boris Johnson may not help battle Covid-19
The research from Brazil found 11 of 65 people treated with tocilizumab died 15 days after getting the drug compared to just two for those who did not get the drug. (Source: the Mail online | Health)
Source: the Mail online | Health - January 21, 2021 Category: Consumer Health News Source Type: news

Arthritis Drug Tocilizumab Flops as COVID-19 Treatment
THURSDAY, Jan. 21, 2021 -- The arthritis drug tocilizumab doesn't help hospital patients with severe COVID-19, according to a new study that contradicts earlier research suggesting that it might aid recovery. In fact, patients receiving tocilizumab... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - January 21, 2021 Category: General Medicine Source Type: news

New trial finds arthritis drug no better than standard care for severe covid-19
(BMJ) Adding the arthritis drug tocilizumab to standard care for patients in hospital with severe or critical covid-19 is no better than standard care alone in improving clinical outcomes at 15 days, finds a new trial published byThe BMJ today. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 20, 2021 Category: International Medicine & Public Health Source Type: news

COVID-19 rapid evidence summary: Tocilizumab for COVID-19 [ES33] NICE (published 15th January 2021)
Unpublished preliminary evidence from the REMAP ‑CAP study has suggested that tocilizumab is beneficial in adults with severe COVID‑19 who are critically ill and receiving respiratory or cardiovascular organ support in an intensive care setting (all randomised within 24 hours of starting organ support). (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - January 15, 2021 Category: Consumer Health News Source Type: news

Arthritis drugs effective in improving survival in sickest COVID-19 patients, NIHR
Results from the REMAP-CAP clinical trial evaluated the effect of treatments on a combination of survival and length of time patients need support in an intensive care unit (ICU). Patients receiving tocilizumab and a second drug called sarilumab - both types of immune modulators - have a significant impact on patient survival and can reduce the relative risk of death by 24% when administered to patients within 24 hours of entering intensive care. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - January 14, 2021 Category: Consumer Health News Source Type: news

UK Approves Arthritis Drugs for Critically Ill COVID-19 Patients
The immunosuppressive drugs tocilizumab and sarilumab improved survival and recovery time of intensive care COVID-19 patients, according to a preprint. (Source: The Scientist)
Source: The Scientist - January 11, 2021 Category: Science Tags: News & Opinion Source Type: news

Interim Position Statement: Interleukin-6 inhibitors (tocilizumab or sarilumab) for patients admitted to ICU with COVID-19 pneumonia (adults), MHRA (issued 8th January 2021)
The REMAP-CAP platform trial has reported survival and time to recovery benefits for tocilizumab or sarilumab. Clinicians should consider prescribing IV tocilizumab (sarilumab an alternative if available) following the criteria defined in this interim position statement. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - January 11, 2021 Category: Consumer Health News Source Type: news

Covid Deaths Lowered in Trial of Tocilizumab and Sarilumab
The big dip in mortality shown in the trial of about 800 patients has caught some experts by surprise because previous studies of the drugs showed little benefit. (Source: NYT Health)
Source: NYT Health - January 8, 2021 Category: Consumer Health News Authors: Katherine J. Wu Tags: Clinical Trials Coronavirus (2019-nCoV) Drugs (Pharmaceuticals) medRxiv Dexamethasone (Drug) Research Immune System Deaths (Fatalities) your-feed-healthcare Source Type: news

Roche, Sanofi Arthritis Drugs Reduce Death Rates Among Sickest COVID-19 Patients   Roche, Sanofi Arthritis Drugs Reduce Death Rates Among Sickest COVID-19 Patients  
Treating critically ill COVID-19 patients with Roche's Actemra or Sanofi's Kevzara arthritis drugs significantly improves survival rates and reduces the amount of time patients need intensive care, study results showed on Thursday.Reuters Health Information (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - January 8, 2021 Category: Orthopaedics Tags: Infectious Diseases News Source Type: news

New Covid drugs ‘significantly’ reduce mortality in critically ill, study finds
Tocilizumab and sarilumab both shown to improve chances of survival and recovery in patients admitted to intensive care (Source: Reuters: Health)
Source: Reuters: Health - January 8, 2021 Category: Consumer Health News Source Type: news